# A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

> **NCT06116136** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Servier Bio-Innovation LLC** · enrollment: 48 (actual)

## Conditions studied

- MSI-H/dMMR Gastroesophageal-junction Cancer
- MSI-H/dMMR Gastric Cancer

## Interventions

- **DRUG:** S095029
- **DRUG:** pembrolizumab 200 mg (KEYTRUDA ®)

## Key facts

- **NCT ID:** NCT06116136
- **Lead sponsor:** Servier Bio-Innovation LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-31
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06116136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06116136, "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06116136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*